RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+7.6%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$696M
AUM Growth
+$696M
(+10%)
Cap. Flow
+$37.9M
Cap. Flow
% of AUM
5.44%
Top 10 Holdings %
Top 10 Hldgs %
28.66%
Holding
112
New
8
Increased
33
Reduced
37
Closed
4
Top Buys
| 1 |
NovoCure
NVCR
|
$21M |
| 2 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
$13.8M |
| 3 |
Exelixis
EXEL
|
$10.3M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$7.96M |
| 5 |
Sanofi
SNY
|
$7.67M |
Top Sells
| 1 |
Amgen
AMGN
|
$11.2M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$10.8M |
| 3 |
Supernus Pharmaceuticals
SUPN
|
$8.62M |
| 4 |
Esperion Therapeutics
ESPR
|
$8.33M |
| 5 |
Biogen
BIIB
|
$5.29M |
Sector Composition
| 1 | Healthcare | 92.59% |
| 2 | Financials | 0.93% |
| 3 | Technology | 0.13% |
| 4 | Energy | 0.1% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $28.8M | 4.13% | 2,422,090 +670,768 | +38% | +$7.96M |
|
|
2
Exelixis
EXEL
$10.1B
| $25.9M | 3.71% | 1,050,000 +420,000 | +67% | +$10.3M |
|
|
3
NovoCure
NVCR
$1.38B
| $21M | 3.02% | +1,216,314 | New | +$21M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $18.7M | 2.69% | 154,000 +42,298 | +38% | +$5.15M |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $18.4M | 2.65% | 142,000 +49,000 | +53% | +$6.36M |
|
6
Gilead Sciences
GILD
$140B
| $18.2M | 2.61% | 256,916 +50,000 | +24% | +$3.54M |
|
7
Incyte
INCY
$16.5B
| $17.6M | 2.53% | 140,046 +25,046 | +22% | +$3.15M |
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $17.2M | 2.47% | 189,300 +64,300 | +51% | +$5.84M |
|
9
Medtronic
MDT
$119B
| $17M | 2.44% | 191,115 +10,000 | +6% | +$887K |
|
|
10
Esperion Therapeutics
ESPR
$448M
| $16.8M | 2.41% | 363,347 -180,000 | -33% | -$8.33M |
|
11
UnitedHealth
UNH
$281B
| $16.7M | 2.4% | 90,000 +25,000 | +38% | +$4.64M |
|
12
Nektar Therapeutics
NKTR
$568M
| $15.5M | 2.23% | 795,000 +325,000 | +69% | +$6.35M |
|
|
ABMD
13
DELISTED
Abiomed Inc
ABMD
| $15.2M | 2.18% | 106,150 -10,898 | -9% | -$1.56M |
|
14
Pfizer
PFE
$141B
| $14.5M | 2.08% | 430,422 +95,000 | +28% | +$3.19M |
|
15
Glaukos
GKOS
$5.5B
| $14.3M | 2.06% | 345,450 +19,650 | +6% | +$815K |
|
|
NDRM
16
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $13.8M | 1.98% | +461,654 | New | +$13.8M |
|
17
Jazz Pharmaceuticals
JAZZ
$7.75B
| $13.2M | 1.9% | 85,020 +24,700 | +41% | +$3.84M |
|
|
18
Biogen
BIIB
$19.4B
| $13.2M | 1.89% | 48,500 -19,500 | -29% | -$5.29M |
|
|
AGN
19
DELISTED
Allergan plc
AGN
| $12.6M | 1.82% | 52,000 -7,000 | -12% | -$1.7M |
|
20
Eli Lilly
LLY
$657B
| $12.3M | 1.77% | 150,000 -20,000 | -12% | -$1.65M |
|
21
Vertex Pharmaceuticals
VRTX
$100B
| $12.2M | 1.76% | 95,013 | – | – |
|
22
Zimmer Biomet
ZBH
$21B
| $11.6M | 1.66% | 90,000 +20,000 | +29% | +$2.57M |
|
|
NVRO
23
DELISTED
NEVRO CORP.
NVRO
| $11.5M | 1.66% | 155,118 +42,504 | +38% | +$3.16M |
|
|
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.3M | 1.49% | 833,154 +117,490 | +16% | +$1.46M |
|
|
ESRX
25
DELISTED
Express Scripts Holding Company
ESRX
| $9.96M | 1.43% | 156,000 +60,000 | +63% | +$3.83M |
|